Skip to main content
DMAC logo

DiaMedica Therapeutics Inc. (DMAC) Stock Price & Analysis

DiaMedica Therapeutics Inc. (DMAC) — MoonshotScore 55/100 (Fair band), calculated Nov 18, 2026. Price $8.25 (+2.87%), as of the Nov 20, 2026 trading session; market cap $445M.

Educational signal · not a buy or sell recommendation · How to read this

$8.25 +$0.23 (+2.87%) Market Cap $445M

DiaMedica Therapeutics Inc. · DMAC · NASDAQ

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and kidney diseases.

Price as of Nov 20, 2026

Key Statistics

55 of 100

MoonshotScore v2 · DiaMedica Therapeutics (DMAC)

Fair
Business Quality Thin (26)
Financial Safety Sound (79)
Valuation Full (44)
Growth Durability Fading (20)
Momentum Surging (90)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Strong price action running well ahead of the business — stalling growth underneath; a move to treat with suspicion, not chase. Business Quality: Thin; Financial Safety: Sound; Valuation: Full; Growth Durability: Fading; Momentum: Surging.

  • EPS beat 1 of the last 8 reports
  • Altman Z 25.78 · Piotroski F 1
  • ROE -94.5% · current ratio 4.76 · earnings yield -8.5% · free-cash-flow yield -7.1%

Holding back: weak fundamentals, soft growth

Helping: balance-sheet strength, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for DMAC (58 recorded, newest six shown)
RecordedScoreBand
57Fair
57Fair
57Fair
55Fair
55Fair
55Fair

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$8.25
Change on the day+2.87%
52-week range$5.25 – $11.00
Market capitalisation$445M—
Shares traded on the day313.5K

Price & events

Other perspectives

Council score for DiaMedica Therapeutics (DMAC): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Weak
Financial Safety Moderate
Valuation Neutral
Growth Durability Weak
Momentum Strong

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Strong
ROE Negative
Gross Margin Negative

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is DiaMedica Therapeutics (DMAC), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. DiaMedica Therapeutics Inc. (DMAC) is listed on NASDAQ. It employs 35 people and is led by Dietrich John Pauls. The market values it at $445M.

2 · Latest results

What do the latest results show for DiaMedica Therapeutics (DMAC)?

Short answer · as of

Against analyst estimates the company has EPS beat 1 of the last 8 reports.

3 · Financial strengths and risks

What are the financial strengths and risks for DiaMedica Therapeutics (DMAC)?

Short answer · as of

The MoonshotScore pillars rate balance-sheet strength, positive momentum as strengths. What is holding it back is weak fundamentals, soft growth. The distress and quality screens read Altman Z 25.78 · Piotroski F 1. Trailing ratios: ROE -94.5% · current ratio 4.76 · earnings yield -8.5% · free-cash-flow yield -7.1%.

Data-derived red flags

  • Negative return on equity (-94.5%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at DiaMedica Therapeutics (DMAC)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $54.00M · EPS -0.77 · 4 analysts.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • No quarterly income statement is held for DMAC.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does DiaMedica Therapeutics compare with its peers?

Short answer

DiaMedica Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Innoviva, Inc. (INVA) Same industry, near in market value$18.41 Nov 20, 2026$1.31B96 5-pillar Nov 18, 2026
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.45 Nov 19, 2026$475M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$8.76 Nov 20, 2026$521M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$2.90 Nov 20, 2026$245M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$40.09 Nov 20, 2026$755M88 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.69 Nov 19, 2026$160M72 5-pillar Nov 18, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$11.54 Nov 20, 2026$817M69 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.84 Nov 20, 2026$174M69 5-pillar Nov 18, 2026
LB Pharmaceuticals Inc (LBRX) Same industry, near in market value$38.85 Nov 20, 2026$1.26B69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.19 Nov 20, 2026$540M68 5-pillar Nov 18, 2026
Vor Biopharma, Inc. (VOR) Same industry, near in market value$19.19 Nov 20, 2026$1.18B66 5-pillar Nov 18, 2026
SpyGlass Pharma, Inc. Common Stock (SGP) Same industry, near in market value$30.43 Nov 20, 2026$1.02B64 5-pillar Nov 18, 2026
DiaMedica Therapeutics (DMAC) — this page$8.25$445M55

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Revenue estimate
$54.00M
EPS estimate
$-0.77

Measured against a quoted price of $8.25 (as of Nov 20, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held DMAC in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported DMAC in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

DiaMedica Therapeutics Stock: Key Questions Answered

These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.

What does the MoonshotScore mean for DMAC?

DMAC carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is DMAC a good stock to buy?

Stock Expert AI does not rate DMAC buy, sell or hold. DiaMedica Therapeutics Inc. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the DMAC stock price today?

The last price recorded for DiaMedica Therapeutics Inc. (DMAC), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the key factors to evaluate for DMAC?

DiaMedica Therapeutics Inc. (DMAC) holds a MoonshotScore in the moderate range. Not financial advice.

How frequently does DMAC data refresh on this page?

DMAC's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven DMAC's recent stock price performance?

DiaMedica Therapeutics Inc. (DMAC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider DMAC overvalued or undervalued right now?

DiaMedica Therapeutics Inc. (DMAC) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of DMAC?

Fractional-share availability for DiaMedica Therapeutics Inc. (DMAC) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

How can I track DMAC's earnings and financial reports?

DiaMedica Therapeutics Inc. (DMAC) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for DMAC earnings announcements.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 15 figures on this page — 4 from Financial Modeling Prep (FMP), 10 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.